Filing Flows › ClearPoint Neuro (CLPT) › Q1 2026
ClearPoint Neuro (CLPT) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
ClearPoint Neuro (CLPT) reported revenue of $12.1M for the first quarter 2026 (Q1 2026), +43% from a year earlier and +17% from the quarter before. Operating margin was -69.9%, net loss $9.6M (78.8% of revenue).
ClearPoint Neuro, Q1 2026: revenue $12.1M (+43% year over year), operating margin -69.9%, net loss $9.6M, operating cash flow −$8.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.1M | +17% | +43% |
| Operating profit | −$8.5M | — | — |
| Net earnings | −$9.6M | — | — |
| Operating cash flow | −$8.0M | — | — |
What changed
Revenue was $12.1M in Q1 2026, up 43% year over year and up 17% from the previous quarter. Biologics and Drug Delivery was the largest line at 40% of revenue. Capital Equipment and Software added $916K year over year (up 177%), 25% of the total change. Capital Equipment and Software Related Service declined 12%.
Gross margin was 64.0%, up 3.5 points from Q1 2025. Operating costs exceeded revenue by $8.5M, an operating margin of -69.9%. Operating expenses grew 44% against revenue growth of 43%. The fastest-growing cost line was Other operating costs (+75%). The quarter ended with a net loss of $9.6M, wider than the previous quarter's $7.8M loss.
Operating cash flow was −$8.0M. Non-cash charges added back $86K of depreciation and amortization and $2.2M of share-based compensation. Working capital and other items used $719K. Capital expenditures of $645K exceeded it, leaving free cash flow of −$8.6M.
Questions
What was ClearPoint Neuro's revenue in the first quarter 2026?
ClearPoint Neuro (CLPT) reported revenue of $12.1M for the first quarter 2026 (Q1 2026), +43% from a year earlier and +17% from the quarter before.
Was ClearPoint Neuro profitable in the first quarter 2026?
Operating loss was $8.5M (-69.9% of revenue) and net loss $9.6M.
Source: ClearPoint Neuro 10-Q on SEC EDGAR.